Latest News & Updates
Breaking News
1 day ago
Simantini Singh Deo
Other trending news you may like to read
DISCO Pharmaceuticals Appoints Mark Manfredi, Ph.D., As CEO And Completes €36 Million Seed Financing To Advance Surfaceome-Targeted Cancer Pipeline
DISCO Pharmaceuticals appoints Mark Manfredi as CEO and secures €36M seed funding to advance its surfaceome-targeted ADC pipeline in SCLC and MSS-CRC.
Simantini Singh Deo
OKYO Pharma Reports New Phase 2 Findings Showing Urcosimod 0.05% Reduces Pain And Improves Corneal Nerve Structure In Patients With Neuropathic Corneal Pain
OKYO Pharma’s Phase 2 trial shows urcosimod improves corneal nerve structure and reduces neuropathic corneal pain, strengthening its first-in-class treatment potential.
Simantini Singh Deo
MAIA Biotechnology Doses First Patient In THIO-104 Phase 3 Trial Testing Ateganosine As A Third-Line Treatment For Advanced NSCLC
MAIA doses the first patient in its THIO-104 Phase 3 trial evaluating ateganosine plus CPI for advanced NSCLC, marking a key step toward potential FDA approval.
Simantini Singh Deo
Abeona Therapeutics Activates UTMB Galveston As New Qualified Treatment Center To Administer FDA-Approved ZEVASKYN Gene Therapy For RDEB Patients
UTMB becomes a Qualified Treatment Center for ZEVASKYN, expanding access to the FDA-approved gene therapy for patients with recessive dystrophic epidermolysis bullosa.
Simantini Singh Deo
